The laboratory of Patrick Green is
internationally recognized for their contributions to the understanding of the
molecular basis of T-lymphocyte transformation and induction of
leukemia/lymphoma and neurological disease by the human T-cell leukemia viruses
(HTLVs). The Green lab has three areas of research focus investigating viral
and cellular regulators of HTLV gene expression/replication, cellular
transformation, and virus survival or persistence in the infected host.
Focus/Project
1
One aim of our laboratory is to understand
the mechanism of action and biological role of a unique HTLV-1 accessory gene,
termed Hbz. It is the only gene transcribed from the antisense strand of
the viral genome and is expressed in almost all adult T-cell leukemia (ATL)
cells, whereas tax oncogene expression is typically undetectable. We
have discovered that HBZ is dispensable in cell culture, but is required to
enhance virus replication and survival in the infected host. More recently
utilizing a Hbz shRNA knockdown approach and NOD/SCIDγc-/-
(NOG) mice we discovered that Hbz expression enhances the proliferative
capacity of HTLV-1 infected cells in culture and plays a critical role in
infected cell survival and ultimately HTLV-1 tumorigenesis. HBZ, originally
thought to be unique to HTLV-1 has been hypothesized to play a role in
pathogenesis. Recently, an antisense protein of HTLV-2 (APH-2)
was identified. Despite its lack of a typical b-ZIP domain, APH-2, like HBZ,
interacts with CREB and down-regulates Tax-mediated viral transcription. We will investigate in detail the mechanism
of action of APH-2. Importantly, since
HTLV-1 and HTLV-2 are closely related retroviruses, but have distinct
etiological roles in human disease, we hypothesize that comparative studies on
anti-sense proteins of HTLV-1 and HTLV-2 will provide fundamental insights into
their distinct pathogenic properties.
Focus/Project
2
A second emphasis of our laboratory
is to understand the mechanism(s) of
post-transcriptional control of viral replication which is critical for HTLV
persistence in the infected host. We have initially focused our studies on the
HTLV regulatory protein Rex which is a critical on/off switch for viral
replication and has been implicated in the transition from early-to-late phase
of HTLV gene expression and potentially influences viral latency and long term
survival in the infected host. We have discovered and are characterizing a
novel carboxy terminal inhibitory domain of Rex that upon phosphorylation
positively regulates Rex function. Mutational analysis and proteomic approaches
are currently underway to precisely map key phosphorylated amino acid residues
and to identify the cellular kinase/phoshatase involved. Furthermore, we have
discovered that one of the HTLV accessory proteins, HTLV-1 p30 and the related
HTLV-2 p28, functions to repress viral replication by a novel
post-transcriptional mechanism. These proteins specifically bind and retain the
mRNA of key positive viral regulators in the nucleus leading to reduced protein
expression and virion production. Current studies are aimed at identifying host proteins
that interact with p30 and p28 in order to understand their role in
pathogenesis. Affinity-tag purification coupled with mass spectrometric (MS)
analysis has revealed 37 and 18 interacting cellular partners of p30 and p28,
respectively. Validation of these proteins is currently underway.
Focus/Project
3
A
third focus of our laboratory is to understand the mechanism(s) by which the
HTLV Tax oncoprotein induces cellular transformation. These studies emphasize
the use of full-length infectious molecular clones of HTLV-1 and the related less
pathogenic HTLV-2, primary human T lymphocytes, and a rabbit animal model. We have previously shown that although Tax is the critical
oncoprotein, which is indispensable for viral replication and cellular
transformation, but it is the viral envelope that dictates the preferential
transformation tropism (CD4 vs CD8 T-cells) of HTLV-1 and HTLV-2. Current studies are underway to dissect the
envelop domain responsible for this distinct transformation tropism.
Preliminary data suggests that this is a post entry event involving selection
and clonal outgrowth.
Research
Support
-
"Mechanisms of Post-Transcriptional Control by
HTLV-p28"
Principle Investigator: Patrick L. Green, Ph.D.
Agency: National Institutes of Health/National Cancer Institute
Type: Project 2 of PO1CA100730
Period: 06/01/08 - 05/31/13
- " Role of viral APH-2 in HTLV-2
replication and persistence"
Principle Investigator: Patrick L. Green, Ph.D.
Agency: National Institutes of Health/National Cancer Institute
Type: R21AI095913
Period:02/01/2012 - 01/31/2014